“We look forward to presenting updated data from our ongoing Phase 2 clinical study of palazestrant in combination with ribociclib in frontline metastatic breast cancer patients at SABCS in December.

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...